Illumina Stock News

Clear Harbor Asset Management LLC boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 35.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,989 shares of the life sciences company’s stock after acquiring an additional 4,156 shares during the quarter. Clear […]

SAN DIEGO, Dec. 23, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: J.P. Morgan Annual Healthcare Conference on January 10, 2022 Presentation at 12:45pm Pacific Time (3:45pm Eastern Time)

SAN DIEGO, Dec. 23, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: J.P. Morgan Annual Healthcare Confere

Illumina, Inc. (NASDAQ:ILMN) has earned an average recommendation of Hold from the twelve brokerages that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokerages []

DUBLIN--(BUSINESS WIRE)--The "Bioinformatics Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global bioinformatics market is expected to grow from $9.38 billion in 2020 to $10.57 billion in 2021 at a compound annual growth rate (CAGR) of 12.7%. The market is expected to reach $18.46 billion in 2025 at a CAGR of 15%. Major players in the bioinformatics market are Agilent Technologies, Illumina, QIAGEN, Affymetrix and

These 3 businesses are industry leaders with strong, long-term competitive moats Check out Lee Ainslie Stock Picks » Download GuruFolio Report of Lee Ainslie (Updated on 12/18/2021) Related Stocks: ILMN , NTRA , TXG , ADPT , FLDM ,

Amalgamated Bank decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.9% during the third quarter, HoldingsChannel reports. The institutional investor owned 32,664 shares of the life sciences companys stock after selling 1,331 shares during the period. Amalgamated Banks holdings in Illumina were worth $13,249,000 as of its most recent SEC filing. Several other []

Understanding the State of the Genomics Market

Veritas Asset Management LLP lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.4% during the third quarter, HoldingsChannel reports. The fund owned 504,922 shares of the life sciences companys stock after selling 2,009 shares during the quarter. Illumina makes up about 1.2% of Veritas Asset Management LLPs portfolio, making the stock its 21st []

Financial Counselors Inc. cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 670 shares of the life sciences companys stock after selling 44 shares during the period. Financial Counselors Inc.s holdings in Illumina []

Financial Counselors Inc. reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 670 shares of the life sciences companys stock after selling 44 shares during the period. Financial Counselors Inc.s []

Using the Seasonal screener to find a seasonal pattern Which stocks are entering into a strong seasonal period in the upcoming days? The Seasonal scre

Related Stocks: STIP , IJJ , HON , HD , VTI , CL , IAU , BSCN , LII , BND , BSCS , BSCR , ILMN , VEEV , SU , SPCE , SLY , MCHP ,

Stephens Investment Management Group LLC cut its holdings in Illumina, Inc. (NASDAQ:ILMN) by 2.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 67,989 shares of the life sciences companys stock after selling 1,665 shares during the period. Stephens []

U.S. life sciences company Illumina on Thursday criticised EU antitrust regulators for scrutinising its $8 billion cash-and-stock takeover of Grail even though the cancer detection test maker has no a